SPOTLIGHT -
EP. 1: Newly Diagnosed MM: Is RVd Still Standard of Care?
EP. 2: Optimizing Therapy for High-Risk Newly Diagnosed MM
EP. 3: Extrapolating from Clinical Trials: Daratumumab in MM
EP. 4: Optimizing Early Sequencing and Treatment in MM
EP. 5: Treatment Approaches in Relapsed Multiple Myeloma
EP. 6: Switching IMiDs: The OPTIMISMM Trial's Impact on MM
EP. 7: Selecting a Proteasome Inhibitor in Multiple Myeloma
EP. 8: Sequencing Through Multiple Lines of Therapy
EP. 9: Using MRD to Determine Cure in Multiple Myeloma
EP. 10: Evaluating MRD's Role in Multiple Myeloma
EP. 11: The Promise of Anti-BCMA CAR T-Cell Therapy in MM
EP. 12: Optimizing the Use of Anti-BCMA Therapy in MM
EP. 13: Considering Selinexor in Penta-Refractory Myeloma
EP. 14: Venetoclax: Potential Use in Multiple Myeloma
EP. 15: Addressing Treatment of Myeloma-Related Comorbidity
EP. 16: Multiple Myeloma: Closing Considerations for Treatment
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
